Shanghai Fudan Forward S&T Co Ltd banner
S

Shanghai Fudan Forward S&T Co Ltd
SSE:600624

Watchlist Manager
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
Watchlist
Price: 4.64 CNY 0.43% Market Closed
Market Cap: ¥3.2B

Multiples-Based Value

The Multiples-Based Value for Shanghai Fudan Forward S&T Co Ltd (600624) under the Base Case is hidden CNY. Compared with the current market price of 4.64 CNY, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Shanghai Fudan Forward S&T Co Ltd Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Shanghai Fudan Forward S&T Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
3.2B CNY 4.8 -26.5 -33.1 -33.1
US
Eli Lilly and Co
NYSE:LLY
869B USD 13.3 42.1 28.4 30.3
US
Johnson & Johnson
NYSE:JNJ
588.6B USD 6.2 22 15.2 18.7
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.4 11.5 13
UK
AstraZeneca PLC
LSE:AZN
227.8B GBP 5.3 30.4 16.8 23.7
US
Merck & Co Inc
NYSE:MRK
297.7B USD 4.6 16.3 10.1 12.3
CH
Novartis AG
SIX:NOVN
231.9B CHF 5.4 21.7 13.4 17.2
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
US
Pfizer Inc
NYSE:PFE
159.7B USD 2.6 20.5 7.8 10.4
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.2 7.6 8.9
US
Bristol-Myers Squibb Co
NYSE:BMY
122.1B USD 2.5 17.3 7.3 9
P/E Multiple
Earnings Growth PEG
CN
S
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
Average P/E: 22.2
Negative Multiple: -26.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.1
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.4
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30.4
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
CH
Novartis AG
SIX:NOVN
21.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.5
22%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
1%
10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
S
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
Average EV/EBITDA: 49.4
Negative Multiple: -33.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.4
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.8
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.4
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
-9%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
S
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
Average EV/EBIT: 108.5
Negative Multiple: -33.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.3
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
13
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23.7
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2
CH
Novartis AG
SIX:NOVN
17.2
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
-4%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.5
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett